Spots Global Cancer Trial Database for medullary thyroid cancer
Every month we try and update this database with for medullary thyroid cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer | NCT04211337 | Medullary Thyro... | Selpercatinib Cabozantinib Vandetanib | 12 Years - | Eli Lilly and Company | |
| An Initial Study of Lithium in Patients With Medullary Thyroid Cancer | NCT00582712 | Medullary Thyro... | Lithium carbona... | 18 Years - | University of Wisconsin, Madison | |
| A Study of TY-1091 in Patients With Advanced Solid Tumors | NCT05675605 | RET-altered Non... Medullary Thyro... RET-altered Pap... Neoplasms | TY-1091 | 18 Years - 100 Years | TYK Medicines, Inc | |
| Amyloid Proteins From Medullary Thyroid Cancer and Laryngeal Amyloidosis | NCT04760171 | Amyloid Medullary Thyro... Alzheimer Disea... Dementia | 18 Years - | The Leeds Teaching Hospitals NHS Trust | ||
| Vandetanib Risk Minimisation Effectiveness | NCT01757470 | Medullary Thyro... | 18 Years - | Sanofi | ||
| A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer | NCT00358956 | Thyroid Cancer | ZD6474 (vandeta... | 18 Years - | Sanofi | |
| SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid Cancer | NCT01625520 | Medullary Thyro... | SOM230 alone or... | 18 Years - 80 Years | Federico II University | |
| Assessing Quality of Life Tools in Medullary Thyroid Cancer Patients | NCT02465424 | Medullary Thyro... | quality of life... | 16 Years - | Velindre NHS Trust | |
| A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) | NCT03157128 | Non-Small Cell ... Medullary Thyro... Colon Cancer Any Solid Tumor | LOXO-292 | 12 Years - | Eli Lilly and Company | |
| A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer | NCT00121628 | Thyroid Cancer | AMG 706 | 18 Years - | Amgen | |
| To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer | NCT01496313 | Thyroid Cancer | 300mg vandetani... 150mg vandetani... | 18 Years - | Sanofi | |
| Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors | NCT02709889 | Malignant Melan... Medullary Thyro... Glioblastoma Large-Cell Neur... Neuroendocrine ... High Grade Gast... Other Neuroendo... Other Solid Tum... | Rovalpituzumab ... Dexamethasone | 18 Years - 99 Years | AbbVie | |
| 68Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTC | NCT06277180 | Medullary Thyro... Prositron Emiss... Fibroblast Acti... Surgery | Surgery Surgery | 18 Years - 75 Years | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma | NCT01661179 | Unresectable Lo... | Vandetanib 300m... | 20 Years - | Sanofi | |
| Cinacalcet to Treat Familial Primary Hyperparathyroidism | NCT00325104 | Hypercalcemia Familial Primar... | Parathyroid hor... Serum calcium t... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Prospective Study Evaluating the Medullary Thyroid Cancer Management's Care Using PET F-DOPA in Patients With a High Level of Postoperative Residual Thyrocalcitonin | NCT02856347 | Medullary Thyro... | 18F-DOPA | 18 Years - | Institut Claudius Regaud | |
| The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer | NCT01739634 | Diarrhea Medullary Thyro... | CASAD | - | Salient Pharmaceuticals Incorporated | |
| Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies | NCT00215605 | Lymphoma Cancer Thyroid Carcino... | XL184 | 18 Years - | Exelixis | |
| Cinacalcet to Treat Familial Primary Hyperparathyroidism | NCT00325104 | Hypercalcemia Familial Primar... | Parathyroid hor... Serum calcium t... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer | NCT01739634 | Diarrhea Medullary Thyro... | CASAD | - | Salient Pharmaceuticals Incorporated | |
| A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC). | NCT04760288 | Medullary Thyro... | Pralsetinib Cabozantinib Vandetanib | 12 Years - | Hoffmann-La Roche | |
| Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma | NCT01661179 | Unresectable Lo... | Vandetanib 300m... | 20 Years - | Sanofi | |
| Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer | NCT00704730 | Thyroid Cancer | XL184 Placebo | 18 Years - | Exelixis | |
| Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer | NCT03630120 | Thyroid Cancer Thyroid Cancer,... Differentiated ... Papillary Thyro... Follicular Thyr... Poorly Differen... | Lenvatinib Sorafenib Cabozantinib Vandetanib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer | NCT03838692 | Medullary Thyro... | Ponatinib | 18 Years - | Columbia University | |
| Radiolabeled Molecules for Medullary Thyroid Cancer | NCT01915485 | Medullary Thyro... | Lu 177 | 18 Years - | Instituto Nacional de Cancer, Brazil | |
| Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor | NCT05278364 | Non-Small Cell ... Medullary Thyro... Solid Tumor | SY-5007 | 18 Years - | Shouyao Holdings (Beijing) Co. LTD | |
| Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation | NCT03906331 | Non Small Cell ... Medullary Thyro... Colon Cancer Breast Cancer Pancreatic Canc... Papillary Thyro... Other Solid Tum... | Selpercatinib | 18 Years - | Eli Lilly and Company | |
| Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001) | NCT06141369 | Adrenal Cortica... Medullary Thyro... Thymic Neuroend... Pancreatic Neur... | individualized ... | 18 Years - | Shanghai Jiao Tong University School of Medicine | |
| Vandetanib Risk Minimisation Effectiveness | NCT01757470 | Medullary Thyro... | 18 Years - | Sanofi | ||
| Thermal Ablation of Cervical Metastases From Thyroid Carcinoma | NCT04522570 | Thyroid Neoplas... Well-Differenti... Medullary Thyro... Lymph Node Meta... | Laser ablation Cryoablation Radiofrequency ... | 18 Years - | Instituto do Cancer do Estado de São Paulo | |
| A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors | NCT03899792 | Medullary Thyro... Infantile Myofi... Infantile Fibro... Papillary Thyro... Soft Tissue Sar... | LOXO-292 | 6 Months - 21 Years | Eli Lilly and Company | |
| A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation | NCT04280081 | Solid Tumor Medullary Thyro... | Selpercatinib | 18 Years - | Eli Lilly and Company | |
| Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors | NCT03037385 | RET-altered Non... Medullary Thyro... RET-altered Pap... RET-altered Col... RET-altered Sol... Lung Neoplasm Carcinoma, Non-... Thyroid Disease... Thyroid Neoplas... Thyroid Cancer,... Carcinoma, Neur... Respiratory Tra... Thoracic Neopla... Neoplasms by Si... Neoplasms Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Endocrine Syste... Endocrine Gland... Head and Neck N... Adenocarcinoma,... Adenocarcinoma Carcinoma Neoplasms, Glan... Neoplasms by Hi... Neuroendocrine ... Neuroectodermal... Neoplasms, Germ... Neoplasms, Nerv... Colonic Neoplas... Colorectal Neop... Intestinal Neop... Gastrointestina... Digestive Syste... Digestive Syste... Gastrointestina... Colonic Disease... Intestinal Dise... | pralsetinib (BL... | 18 Years - | Hoffmann-La Roche | |
| Vandetanib Risk Minimisation Effectiveness | NCT01757470 | Medullary Thyro... | 18 Years - | Sanofi | ||
| Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic Colon Cancer | NCT02363647 | Medullary Thyro... Colon Cancer | Tumor Genomic A... | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| 68Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTC | NCT06277180 | Medullary Thyro... Prositron Emiss... Fibroblast Acti... Surgery | Surgery Surgery | 18 Years - 75 Years | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer | NCT03838692 | Medullary Thyro... | Ponatinib | 18 Years - | Columbia University | |
| Predictive Factors for Medullary Thyroid Cancer Aggressiveness | NCT06292988 | Medullary Thyro... | Total Thyroidec... | 18 Years - | Aristotle University Of Thessaloniki | |
| Expanded Access of Cabozantinib in Medullary Thyroid Cancer | NCT01683110 | Medullary Thyro... | cabozantinib | 18 Years - | Exelixis | |
| 68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access) | NCT02174679 | Carcinoid Cance... Neuroendocrine ... Medullary Thyro... Cancers Express... | 68Ga DOTATATE | 18 Years - | Jonsson Comprehensive Cancer Center | |
| A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors | NCT03899792 | Medullary Thyro... Infantile Myofi... Infantile Fibro... Papillary Thyro... Soft Tissue Sar... | LOXO-292 | 6 Months - 21 Years | Eli Lilly and Company | |
| A Detailed Look At What Patients Experience In Medullary Thyroid Cancer Clinical Study | NCT06079723 | Medullary Thyro... | 18 Years - | Power Life Sciences Inc. | ||
| Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer | NCT00704730 | Thyroid Cancer | XL184 Placebo | 18 Years - | Exelixis | |
| Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC | NCT04204928 | Non-Small Cell ... Medullary Thyro... | pralsetinib (BL... | 12 Years - | Blueprint Medicines Corporation | |
| Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors | NCT02709889 | Malignant Melan... Medullary Thyro... Glioblastoma Large-Cell Neur... Neuroendocrine ... High Grade Gast... Other Neuroendo... Other Solid Tum... | Rovalpituzumab ... Dexamethasone | 18 Years - 99 Years | AbbVie | |
| Is Desmoplastic Stromal Reaction Useful to Modulate Lymph Node Dissection in Sporadic Medullary Thyroid Carcinoma? | NCT06243965 | Medullary Thyro... Medullary Carci... Medullary Tumor Medullary Neopl... Desmoplasia Desmoplastic Desmoplastic Re... Lymph Node Meta... Lymph Node Dise... | 18 Years - | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | ||
| Assessing Quality of Life Tools in Medullary Thyroid Cancer Patients | NCT02465424 | Medullary Thyro... | quality of life... | 16 Years - | Velindre NHS Trust | |
| A Study of TY-1091 in Patients With Advanced Solid Tumors | NCT05675605 | RET-altered Non... Medullary Thyro... RET-altered Pap... Neoplasms | TY-1091 | 18 Years - 100 Years | TYK Medicines, Inc | |
| The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer | NCT01739634 | Diarrhea Medullary Thyro... | CASAD | - | Salient Pharmaceuticals Incorporated | |
| A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC) | NCT00923247 | Medullary Thyro... | Bortezomib Vandetanib | 18 Years - 80 Years | National Institutes of Health Clinical Center (CC) | |
| Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor | NCT05278364 | Non-Small Cell ... Medullary Thyro... Solid Tumor | SY-5007 | 18 Years - | Shouyao Holdings (Beijing) Co. LTD | |
| A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer | NCT01896479 | Medullary Thyro... | Cabozantinib (X... Cabozantinib (X... Placebo tablet Placebo capsule | 18 Years - | Exelixis | |
| An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer | NCT00410761 | Thyroid Cancer | ZD6474 (Vandeta... | 18 Years - | Sanofi | |
| Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma | NCT05830500 | Medullary Thyro... | Anlotinib Hydro... | 18 Years - 75 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors | NCT03780517 | Advanced Nonhae... | BOS172738 | 18 Years - | Boston Pharmaceuticals |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
